In a report released today, Clara Dong from Jefferies downgraded Astria Therapeutics to a Hold, with a price target of $13.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Clara Dong has given her Hold rating due to a combination of factors surrounding the acquisition of Astria Therapeutics by BCRX. The acquisition, valued at approximately $700 million, represents a strategic fit for BCRX’s existing hereditary angioedema (HAE) portfolio, particularly with the inclusion of Astria’s lead candidate, Navenibart. This long-acting injectable aligns well with BCRX’s current offerings and could enhance their market presence in the HAE space.
Despite the promising integration of Navenibart, which has shown strong efficacy in reducing HAE attacks, Clara Dong’s Hold rating reflects a cautious stance. The acquisition is expected to close in Q1 2026, and while there is potential for significant market share capture and revenue growth, the timeline for realizing these benefits extends into the future. Additionally, the competitive landscape, including existing treatments like Takhzyro, poses challenges that temper immediate expectations for the stock’s performance.